Dendritic Cell Preparation via Platelet Lysate Non-Adhesion Culture

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional methods for preparing dendritic cells from monocytes are insufficient in terms of yield and do not produce cells with strong cytotoxic activity, which is desirable for cancer treatment.

Innovation Solution

A method involving non-adhesion culture of monocytes with a serum-free medium containing human platelet lysate (HPL), GM-CSF, PEGylated interferon α, prostaglandin E2, and OK432 enhances the yield and functionality of dendritic cells, including their cytotoxic activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional adhesion culture methods are used with GM-CSF and IL-4, then dendritic cells can be differentiated, but the yield is insufficient and cytotoxic activity is weak

Engineering Contradiction:

Improveyield of dendritic cellsVSAvoidcytotoxic activity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention changes the culture method from adhesion culture to non-adhesion (suspension) culture, and modifies the cytokine composition by replacing IL-4 with PEGylated interferon α and adding platelet lysate. These parameter changes result in significantly improved DC yield (15% or higher) and strong cytotoxic activity with CD16 and CD56 expression, resolving the contradiction between productivity and reliability.

Inventive Principle:

Principle #35Parameter changes

2Loss of time

If adhesion culture is performed with physical stripping, then cells can be collected, but the process is time-consuming and yield is limited

Engineering Contradiction:

Improveculture timeVSAvoidyield of dendritic cells

Core Design Contradiction:

Loss of timeVSProductivity

Solution Approach 1:

The invention inverts the conventional approach by using non-adhesion culture instead of adhesion culture. Monocytes are cultured in suspension without adhering to the culture vessel wall, eliminating the need for physical stripping. This inversion reduces culture time to 2-5 days while significantly improving DC yield to 15% or higher, simultaneously addressing both time loss and productivity.

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If conventional methods are used, then dendritic cells can be prepared, but they lack strong cytotoxic activity required for cancer treatment

Engineering Contradiction:

Improvecytotoxic activityVSAvoidyield of dendritic cells

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The invention uses a composite cytokine system consisting of platelet lysate (containing multiple growth factors), GM-CSF, and PEGylated interferon α. This composite approach creates dendritic cells with enhanced functionality including strong cytotoxic activity (CD16+, CD56+) while maintaining high yield (15% or higher), resolving the contradiction between reliability and productivity.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20240010978A1Method for preparing dendritic cell using platelet lysate

Publication Date: 2024.01.11 ALP REGENERATIVE MEDICINE INSTITUTE INC

AI summary

This invention provides a method for preparing dendritic cells from monocytes using a platelet lysate. This invention also provides a method for preparing cytotoxic dendritic cells from monocytes comprising performing non-adhesion culture of monocytes separated from the peripheral blood using a serum-free medium containing a human platelet lysate (HPL), GM-CSF, and PEGylated interferon α and performing further non-adhesion culture with the addition of prostaglandin E2 and OK432.